|
In the Media
June 10, 2010
Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO
Doctor's Guide published an article 06.09.2010 titled "Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO"
reporting on the Phase 2 PV-10 for metastatic melanoma clinical data presented at ASCO 2010 by lead investigator Sanjiv Agarwala, MD.
June 7, 2010
Provectus Presents at ASCO
Additional positive data from the Phase 2 clinical trial of PV-10 for metastatic melanoma was presented by Dr. Sanjiv
Agarwala at the American Society of Clinical Oncology 2010 Annual Meeting, on Sunday, June 6, 2010, in the General Poster
Session on Melanoma/Skin Cancers. The poster may be viewed at
http://www.pvct.com/publications/ASCO_Poster-2010.pdf.
May 21, 2010
Provectus Presenting at SCIA Summer Conference
The Southern California Investment Association has announced that
Provectus will be presenting at the SCIA Summer Conference. The SCIA Summer Conference will be held Saturday June 5, 2010
at the Hilton Hotel/Orange County Airport in Irvine, CA.
UPDATE: Video interview of Craig Dees, Ph.D.
on
SNN Live
View the article.
April 1, 2010
New era in metastatic melanoma
An article entitled "New era in metastatic melanoma", appearing in the April 2010 edition
of Molecular Oncology, highlights promising
new therapies for the treatment of late stage metastatic melanoma. PV-10 is discussed in section 7
of the article and includes comments by Dr. Sanjiv Agarwala, a principal investigator of the Phase 2 study.
View the article.
March 12, 2010
Provectus CEO Craig Dees, Ph.D. Interviewed by CEOCFO
An interview with Provectus' CEO Craig Dees, Ph.D., appeared in the March 12, 2010 issue of
CEOCFO (www.ceocfointerviews.com). In the interview,
Dr. Dees explains how Provectus' technology is very different from current cancer treatments and answers
questions regarding the current status of clinical trials, the Compassionate Use program for melanoma patients,
and Provectus' financial picture and strategy.
The article is available on the Provectus website.
March 2, 2010
Provectus Added to the Mentor Capital Cancer Immunotherapy Index
Mentor Capital, Inc. has added Provectus to their Cancer Immunotherapy Index. The
Cancer Immunotherapy Index is available at MentorCapital.com.
UPDATE:
Mentor Capital Cancer Immunotherapy Index Gains are Triple that of the Overall Market Appreciation.
|
